— Enrollment was stopped earlier than prepared after interim analysis
by Kristina Fiore, Director of Enterprise & & Investigative Reporting, MedPage Today
June 30, 2023
Registration into a little trial of nirmatrelvir/ritonavir (Paxlovid) for long COVID– one that formerly amassed attention for private investigators not using masks– has actually been stopped early after an interim analysis, Stanford University verified to MedPage Today
2 sources acquainted with the STOP-PASC research study informed MedPage Today that trial registration had actually been stopped. One was informed by a research study organizer that an initial evaluation discovered “undetermined proof” for the main result of the research study. Another stated their very first consultation was canceled simply a couple of days prior to it was expected to happen, and they were later on informed that all future registration had actually been stopped.
“I’ve had neurological long COVID for more than 2 years and this was the very first time I had a chance to take part in a trial screening a prospective drug treatment,” the individual whose check out was canceled informed MedPage Today“I was so excited to provide it a shot, I invested cash from my diminishing cost savings account to spend for [my] journeys.”
Stanford Medicine representative Lisa Kim verified that “brand-new registration is closing somewhat earlier than initial forecasts based upon a prepared interim analysis examined by an external tracking committee.”
“There are no security worry about the research study and registered individuals are motivated to finish follow-up activities as prepared,” she included.